Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries

Nature Biotechnology

Volumn 16, Issue 1, 1998, Pages 59-63

  Ho, Siew Peng ^a   Bao, Yijia ^a   Lesher, Treena ^a   Malhotra, Rohit ^a   Ma, L Y ^b   Fluharty, Steve J ^b   Sakai, Randall R ^b  

^a DUPONT COMPANY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiotensin type 1 receptor; Antisense; Oligonucleotide libraries; RNA mapping

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID DERIVATIVE; RIBONUCLEASE H;

ARTICLE; AUTORADIOGRAPHY; CELL CULTURE; FLUID INTAKE; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; RNA ANALYSIS; RNA HYBRIDIZATION; RNA SEQUENCE;

ANIMALS; BASE SEQUENCE; CHIMERA; CHO CELLS; CHROMOSOME MAPPING; CRICETINAE; GENE LIBRARY; MALE; MOLECULAR SEQUENCE DATA; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE PROBES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RIBONUCLEASE H, CALF THYMUS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 0003038882     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0198-59     Document Type: Article

References (22)

1. Raffa, R.B. and Porreca, F. 1996. Antisense strategies for the study of receptor mechanisms. Chapman & Hall, London.
2. Agrawal, S. 1996. Antisense therapeutics. Humana Press, Totawa, NJ.
3. Akhtar, S. 1995. Delivery strategies for antisense oligonucleotide therapeutics. CRC Press, Boca Raton, FL
4. Szymkoswki, D.E. 1996. Developing antisense oligonucleotides from the laboratory to clinical trials. Drug Discovery Today 1:415-428.
5. Gewirtz, A.M., Stein, C.A., and Glazer, P.M. 1996. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci. USA 93:3161-3163.
6. Peyman, A., Helsberg, M., Kretzschmar, G., Mag, M., Grabley, S., and Uhlmann, E. 1995. Inhibition of viral growth by antisense olginucleotides directed against the IE110 and the UL30 mRNA of Herpes Simplex Virus type-1. Biol. Chem 376:195-198.
7. Monia, B.P., Johnston, J.F., Geiger, T., Muller, M., and Fabbro, D. 1996. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2:668-675.
8. Dean, N.M., McKay, R., Condon, T.P., and Bennett, C.F. 1994. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. 269:16416-16424.
9. Ho, S.P., Britton, D.H.O., Stone, B.A., Behrens, D.L., Leffet, L.M., Hobbs, F.W., et al. 1996. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucl. Acids Res. 24:1901-1907.
10. Condon, T.P. and Bennett, C.F. 1996. Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells. J. Biol. Chem. 271:30398-30403.
11. Monia, B.P., Lesnik, E.A., Gonzalez, C., Lima, W.F., McGee, D., Guinosso, C.J., et al. 1993. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:14514-14522.
12. Giles, R.V., Spiller, D.G., and Tidd, D.M. 1995. Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res. Dev. 5:23-31.
13. Inoue, H., Hayase, Y., Iwai, S., and Ohtsuka, E. 1987. Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS Lett. 215:327-330.
14. Crooke, S.T., Lemonidis, K.M., Neilson, L., Griffey, R., Lesnik, E.A., and Monia, B.P. 1995. Kinetic characteristics of Escherichia coli RNase H: cleavage of various antisense oligonucleotide-RNA duplexes. Biochemistry Journal 312:599-608.
15. Lima, W.F., Mohan, V., and Crooke, S.T. 1997. The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity. J. Biol. Chem. 272:18191-18199.
16. Sakai, R.R., He, P.F., Yang, X.D., Ma, L.Y., Guo, Y.F., Reilly, J.J., et al. 1994. Intracerebroventricular administration of AT, receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II. J. Neurochem. 62:2053-2056.
17. Lima, W.F., Brown-Driver, V., Fox, M., Hanecak, R., and Bruice, T.W. 1997. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J. Biol. Chem. 272:626-638.
18. Birikh, K.R., Berlin, Y.A., Soreq, H., and Eckstein, F. 1997. Probing accessible sites for ribozymes on human acetylcholinesterase RNA. RNA 3:429-437.
19. Milner, N., Mir, K.U., and Southern, E.M. 1997. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nature Biotechnology 15:537-544.
20. Lieber, A. and Strauss, M. 1995. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol. Cell. Biol. 15:540-551.
21. Chiu, A.T., Dunscomb, J., McCall, D.E., Benfield, P., Baubonis, W., and Sauer, B. 1993. Characterization of angiotensin AT1 a receptor isoform by its ligand binding signature. Regulatory Peptides 44:141-147.
22. Chiu, A.T., Dunscomb, J., McCall, D.E., Benfield, P., Baubonis, W., and Sauer, B. 1993. Characterization of angiotensin AT1a receptor isoform by its ligand binding signature. Regul. Pept. 44:141-147.